2 results
Approved WMOCompleted
Primary objective: To demonstrate that QVA149 (110/50 *g o.d.) is at least non-inferior to salmeterol/fluticasone (50/500 *g b.i.d.) in terms of rate of COPD exacerbations.Secondary objectives: Superiority in terms of exacerbation rate. Time to…
Approved WMORecruiting
The study aim is to examine different doses of Naronapride film-coated tablets (for oral intake) versus placebo in patients with idiopathic or diabetic gastroparesis. In previous clinical trials, Naronapride has been administered to more than 900…